The results were published in the New England Journal of Medicine in 2021.1
How the trial was run
STEP 1 was the first trial of the STEP series, which went on to test semaglutide 2.4 mg in other groups and settings. Participants had a body mass index of 30 or more, or 27 or more with at least one weight-related condition. Two in three were assigned to semaglutide and one in three to placebo. Both groups also received a lifestyle program of diet and physical activity counseling.1
The Wegovy label that grew out of these trials climbs from 0.25 mg to 2.4 mg over 16 weeks, in steps of 0.25, 0.5, 1 and 1.7 mg, four weeks each.2 The trial's main analysis counted everyone as assigned, whether or not they kept taking the drug, which makes its results closer to real use than counts limited to people who stayed on treatment.1
What it found
- Weight fell by 14.9% on semaglutide against 2.4% on placebo, a difference of 12.4 percentage points.
- In kilograms, the average loss was 15.3 against 2.6.
- A loss of 5% or more was reached by 86.4% against 31.5%; 10% or more by 69.1% against 12.0%; 15% or more by 50.5% against 4.9%.
- Heart and metabolic risk factors and self-reported physical functioning improved more on semaglutide.
Wilding et al., 2021.1
The Wegovy label reports the same trial with its own counting method and gives slightly lower shares: 83.5% reaching 5% and 47.9% reaching 15%, against 31.1% and 4.8% on placebo, from a starting weight of about 105 kg.2 Both describe the same people; the gap comes from how missing data were handled. Our Wegovy weight loss chart shows how the loss builds week by week.
Side effects
Nausea and diarrhea were the most common side effects of semaglutide, usually short-lived, mild to moderate, and easing with time. Stomach and gut events led 4.5% on semaglutide to stop treatment, against 0.8% on placebo.1 Across the Wegovy weight trials, nausea was reported by 44% on the drug against 16% on placebo.2 Our page on nausea on a GLP-1 covers what helps.
Why it matters
Liraglutide 3 mg, the earlier GLP-1 medicine for weight, lowered weight by 7.4% against 3.0% on placebo over 56 weeks in its own trial, a difference of 4.4 points.3 STEP 1 nearly tripled the difference over placebo, to 12.4 points, with a weekly rather than daily injection, and it set the benchmark that later trials, including those of tirzepatide, are measured against.
It also left a question that later STEP trials took up: what happens when people stop. STEP 4 tested stopping after 20 weeks: from week 20 to week 68, people who stayed on semaglutide lost another 7.9%, while those switched to placebo regained 6.9%.4 STEP 2 tested the same dose in 1,210 people with type 2 diabetes, where weight fell by 9.6% against 3.4% on placebo, a smaller loss than without diabetes.5
Limits
The trial was funded by Novo Nordisk, the maker of semaglutide, and it excluded people with diabetes. Like most weight trials it lasted just over a year, so it cannot show what happens over many years of use.1
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. Funded by Novo Nordisk; NCT03548935. doi:10.1056/NEJMoa2032183
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2, 6.1 and 14. accessdata.fda.gov
- SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published June 15, 2026; section 14. dailymed.nlm.nih.gov
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA 2021;325:1414-1425. doi:10.1001/jama.2021.3224
- Davies M, F忙rch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet 2021;397:971-984. doi:10.1016/S0140-6736(21)00213-0
Related analyses
Wegovy weight loss chart: the trial results week by week, in your own weight
Wegovy dosing schedule: the injection, the new 7.2 mg dose and the tablets, with your dates
Ozempic vs Wegovy: the same drug under two labels, compared by dose, results and price
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Log your weight weekly and see how your curve compares with the trial's.
Open Dose Insider